Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis

NCT01988103 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

254

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis
Psoriatic Arthritis
Psoriasis Arthropatica

Interventions

DRUG: Apremilast
DRUG: Apremilast
DRUG: Placebo

Sponsor

Amgen